But when intellectual property is involved, that need has to be balanced with the seller's desire not to divulge too much about a patented secret. Striking that balance has been the challenge for companies attempting to set up B2B intellectual property exchanges in the life sciences. You talk about the problem, you don't solve it. You talk about the technology in terms of what it can do, what it has achieved, but not sufficient knowledge that you would disclose the inner workings of it. ActiveCyte, which focuses on biotech, asked pharmaceutical companies for their help designing its standard.
Users can search by criteria, and connect to other databases.
Intellectual property B2B executives say they know their service is only a beginning, and with so much at stake, any introduction is followed by months of due diligence and negotiation. All rights reserved. By using Austin360 you accept the terms of our visitor agreement . Registered site users, use this link to edit your personal profile .